Login to Your Account



Amicus sees long route to Fabry drug approval

By Michael Fitzhugh
Staff Writer

Tuesday, November 29, 2016

About a year after the outlook for speedy U.S. approval of Fabry disease drug migalastat turned from sunny to sober on FDA feedback, Amicus Therapeutics Inc. said new talks with the agency yielded a path to full approval.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription